Patent · US Active

Chimeric MOMP antigen

US8735543B2 · kind B2 · utility

1Cited by

6References

20Claims

0Family size

Assignee

Spixia Biotechnology AB · SE

Inventors

Soren Andersson · Sollentuna, SE
Åke Strid · Örebro, SE

Key dates

Filing date	May 27, 2011
Grant date	May 27, 2014
Priority date	—
Expiry date	May 27, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/40
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention regards polypeptides capable of eliciting an immunological response that is protective against Chlamydia trachomatis. The polypeptide comprises a first amino acid sequence which has at least 90% homology with the amino acid sequence according to SEQ ID NO: 1 and a second amino acid sequence which has at least 90% homology with the amino acid sequence according to SEQ ID NO: 2. Furthermore, production of these polypeptides and pharmaceutical compositions comprising them are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.